Page 270 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 270
Viral Hepatitis: Hepatitis C - Clinical (Therapy) (Cont.)
P0863 “REAL-LIFE”-EXPERIENCE WITH SECOND GENERATION
DIRECT ACTING ANTIVIRAL (DAA) TREATMENT IN HCV
PATIENTS (N=149)
Christoph R. Werner*, Daniel P. Egetemeyr, Nisar P. Malek,
Ulrich M. Lauer, Christoph P. Berg, Germany
P0864 THE IMPACT OF RIBAVIRIN ON REAL WORLD ADHERENCE
AND DISCONTINUATION RATES IN HCV PATIENTS
TREATED WITH SOFOSBUVIR+SIMEPREVIR
David R. Walker, Timothy R. Juday*, Shivaji R. Manthena,Yonghua Jing,
Vipan Sood, The United States
P0865 THE USE OF SOFOSBUVIR BASED REGIMENS AMONGST
TREATMENT NAIVE AND EXPERIENCED PATIENTS WITH
ADVANCED FIBROSIS/CIRRHOSIS: REAL WORLD RESULTS
FROM A DIFFICULT TO TREAT COHORT
Diarmid Sutherland*, Shouren Datta, Ewan H. Forrest, Raymond Fox,
Mathis Heydtmann, Matthew Priest, Peter R. Mills, Judith Morris,
Adrian J. Stanley, Stephen T. Barclay, The United Kingdom
ePOSTERS P0866 COMPARATIVE EFFICACY AND TOLERABILITY OF
DACLATASVIR + SOFOSBUVIR VERSUS SOFOSBUVIR +
RIBAVIRIN FOR HEPATITIS C GENOTYPE 3: A MATCHING-
ADJUSTED INDIRECT COMPARISON
Elyse Swallow, Jinlin Song,Yong Yuan*, Anupama Kalsekar,
Caroline Kelley, Fan Mu, Soomi Kim, Stephanie Noviello,
James Signorovitch, The United States
P0867 EFFICACY EVALUATION OF 24 WEEK SOF + RBV IN A
HETEROGENEOUS, REAL-WORLD POPULATION OF
GENOTYPE 3 HCV PATIENTS; DATA FROM THE TRIO
NETWORK
Kris Kowdley*, Bruce Bacon, Douglas Dieterich, Eric Lawitz,
Scott Milligan, Naoky Tsai, Zobair Younossi, Steven Flamm,
The United States
P0868 MODELING COST-EFFECTIVENESS DURING ANTIVIRAL
THERAPY FOR CHRONIC HEPATITIS C IN REAL-LIFE
PRACTICE BY GENETIC TESTS AND VIRAL KINETIC
PROFILE
Liliana Chemello*, Elisabetta Bugin, Gianluca Furneri, Katia Bortolozzo,
Angelo Gatta, Luisa Cavalletto, Italy
270 The International Liver Congress™ 2015 • ILC Programme
P0863 “REAL-LIFE”-EXPERIENCE WITH SECOND GENERATION
DIRECT ACTING ANTIVIRAL (DAA) TREATMENT IN HCV
PATIENTS (N=149)
Christoph R. Werner*, Daniel P. Egetemeyr, Nisar P. Malek,
Ulrich M. Lauer, Christoph P. Berg, Germany
P0864 THE IMPACT OF RIBAVIRIN ON REAL WORLD ADHERENCE
AND DISCONTINUATION RATES IN HCV PATIENTS
TREATED WITH SOFOSBUVIR+SIMEPREVIR
David R. Walker, Timothy R. Juday*, Shivaji R. Manthena,Yonghua Jing,
Vipan Sood, The United States
P0865 THE USE OF SOFOSBUVIR BASED REGIMENS AMONGST
TREATMENT NAIVE AND EXPERIENCED PATIENTS WITH
ADVANCED FIBROSIS/CIRRHOSIS: REAL WORLD RESULTS
FROM A DIFFICULT TO TREAT COHORT
Diarmid Sutherland*, Shouren Datta, Ewan H. Forrest, Raymond Fox,
Mathis Heydtmann, Matthew Priest, Peter R. Mills, Judith Morris,
Adrian J. Stanley, Stephen T. Barclay, The United Kingdom
ePOSTERS P0866 COMPARATIVE EFFICACY AND TOLERABILITY OF
DACLATASVIR + SOFOSBUVIR VERSUS SOFOSBUVIR +
RIBAVIRIN FOR HEPATITIS C GENOTYPE 3: A MATCHING-
ADJUSTED INDIRECT COMPARISON
Elyse Swallow, Jinlin Song,Yong Yuan*, Anupama Kalsekar,
Caroline Kelley, Fan Mu, Soomi Kim, Stephanie Noviello,
James Signorovitch, The United States
P0867 EFFICACY EVALUATION OF 24 WEEK SOF + RBV IN A
HETEROGENEOUS, REAL-WORLD POPULATION OF
GENOTYPE 3 HCV PATIENTS; DATA FROM THE TRIO
NETWORK
Kris Kowdley*, Bruce Bacon, Douglas Dieterich, Eric Lawitz,
Scott Milligan, Naoky Tsai, Zobair Younossi, Steven Flamm,
The United States
P0868 MODELING COST-EFFECTIVENESS DURING ANTIVIRAL
THERAPY FOR CHRONIC HEPATITIS C IN REAL-LIFE
PRACTICE BY GENETIC TESTS AND VIRAL KINETIC
PROFILE
Liliana Chemello*, Elisabetta Bugin, Gianluca Furneri, Katia Bortolozzo,
Angelo Gatta, Luisa Cavalletto, Italy
270 The International Liver Congress™ 2015 • ILC Programme
